IPG11406

DRUG3 trials

Sponsors

Nanjing Immunophage Biotech Co., Ltd

Conditions

Inflammatory Bowel DiseasesLupus NephritisModerately to Severely Active Ulcerative Colitis (UC)

Phase 1

Phase 1 Study for IPG11406 in Health Volunteer

CompletedNCT06255834

Nanjing Immunophage Biotech Co., LtdInflammatory Bowel Diseases

Start: 2024-02-24End: 2024-12-30Updated: 2026-04-17

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

CompletedNCT06717815

Nanjing Immunophage Biotech Co., LtdLupus Nephritis

Start: 2025-02-25End: 2026-06-08Updated: 2026-09-09

Phase 2

Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

Not yet recruitingNCT07535489

Nanjing Immunophage Biotech Co., LtdModerately to Severely Active Ulcerative Colitis (UC)

Start: 2026-07-07End: 2029-12-01Target: 144Updated: 2026-04-17